- Home
- DMO vs CRVS Comparison
DMO vs CRVS Comparison
Compare DMO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMO
- CRVS
- Stock Information
- Founded
- DMO 2009
- CRVS 2014
- Country
- DMO United States
- CRVS United States
- Employees
- DMO N/A
- CRVS N/A
- Industry
- DMO Trusts Except Educational Religious and Charitable
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- DMO Finance
- CRVS Health Care
- Exchange
- DMO Nasdaq
- CRVS Nasdaq
- Market Cap
- DMO 136.1M
- CRVS 161.4M
- IPO Year
- DMO N/A
- CRVS 2016
- Fundamental
- Price
- DMO $12.05
- CRVS $6.03
- Analyst Decision
- DMO
- CRVS Buy
- Analyst Count
- DMO 0
- CRVS 3
- Target Price
- DMO N/A
- CRVS $5.75
- AVG Volume (30 Days)
- DMO 49.6K
- CRVS 414.7K
- Earning Date
- DMO 01-01-0001
- CRVS 11-05-2024
- Dividend Yield
- DMO 12.06%
- CRVS N/A
- EPS Growth
- DMO N/A
- CRVS N/A
- EPS
- DMO N/A
- CRVS N/A
- Revenue
- DMO N/A
- CRVS N/A
- Revenue This Year
- DMO N/A
- CRVS N/A
- Revenue Next Year
- DMO N/A
- CRVS N/A
- P/E Ratio
- DMO N/A
- CRVS N/A
- Revenue Growth
- DMO N/A
- CRVS N/A
- 52 Week Low
- DMO $10.00
- CRVS $1.05
- 52 Week High
- DMO $11.80
- CRVS $5.22
- Technical
- Relative Strength Index (RSI)
- DMO 52.57
- CRVS 80.19
- Support Level
- DMO $11.90
- CRVS $3.90
- Resistance Level
- DMO $12.14
- CRVS $4.75
- Average True Range (ATR)
- DMO 0.11
- CRVS 0.39
- MACD
- DMO 0.01
- CRVS 0.10
- Stochastic Oscillator
- DMO 57.58
- CRVS 98.07
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).